킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

American Diabetes Association 81st Scientific Sessions (ADA 2021)

25 June - 29 June, 2021, United States

Artificial pancreas supports glucose control, even in ‘terrible twos’

2021-11-12

An automated insulin delivery system, also referred to as artificial pancreas, helps improve glycaemic control in children with type 1 diabetes (T1D) in a study presented at ADA 2021.
Dorzagliatin a new hope for T2D

2021-11-12

In drug-naïve Chinese patients with type 2 diabetes (T2D), treatment with the first-in-class, glucose sensitizer dorzagliatin led to sustained glycaemic control, according to updated findings from the 52-week phase III SEED* study presented at ADA 2021.
Efpeglenatide reduces MACE, kidney events in high-risk patients with T2D

2021-11-12

In patients with type 2 diabetes (T2D) with cardiovascular (CV) risk factors or impaired kidney function, weekly doses of the exendin-based GLP-1* receptor agonist (RA) efpeglenatide may reduce their risk of major adverse cardiovascular events (MACE) or kidney outcomes, according to findings from the AMPLITUDE-O trial presented at ADA 2021.
Ertugliflozin improves glycaemic outcomes in patients with stage 3 CKD

2021-11-12

Ertugliflozin significantly improves glycaemic outcomes in patients with type 2 diabetes (T2D) who have stage 3 chronic kidney disease (CKD), according to a subgroup analysis of the VERTIS CV* trial presented at ADA 2021.
iGlarLixi trumps biphasic insulin for glycaemic control, weight loss in poorly controlled T2D

2021-11-12

Once-daily iGlarLixi is superior to twice-daily premixed biphasic insulin aspart 30 (BIAsp 30) in glycaemic control and reducing body weight, along with less risk of hypoglycaemia, in patients with suboptimally controlled type 2 diabetes (T2D) despite treatment with basal insulin plus oral antihyperglycaemic drugs (OADs), according to the SoliMix trial presented at ADA 2021.
Semaglutide: Four STEPs ahead in obesity care

2021-11-12

With four STEP* studies published on the profound impact that semaglutide 2.4 mg confers on weight loss, these indicate GLP-1 signalling as a powerful and effective target for obesity therapy and thus, usher in a new era for obesity care, said a leading expert during the ADA 2021 session.
Sotagliflozin SCOREs in T2D patients with kidney disease

2021-11-12

The dual SGLT1/2* inhibitor sotagliflozin significantly lowers the risk of the composite outcome of cardiovascular (CV) deaths, hospitalizations for heart failure (HHF), and urgent visits for heart failure in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), regardless of albuminuria status, according to the SCORED trial presented at ADA 2021.
SUSTAIN FORTE reinforces semaglutide 2.0 mg for poorly controlled T2D

2021-11-12

The investigational 2.0-mg dose of semaglutide provided greater reductions in glycated haemoglobin (HbA1c) and body weight than semaglutide 1.0 mg in the phase IIIb SUSTAIN FORTE trial.
Time-restricted eating for weight loss: The jury is still out

2021-11-12

Time-restricted eating (TRE) could provide a modest 1–4 percent weight loss without cutting calories, says an expert. But whether the evidence on hand supports its use is still debatable.
Tirzepatide SURPASSes semaglutide for HbA1c reductions, weight loss

2021-11-12

In patients with type 2 diabetes (T2D), once-weekly doses of the dual glucose-dependent insulinotropic polypeptide–GLP-1* receptor agonist tirzepatide for 40 weeks resulted in superior HbA_1c reductions compared with the GLP-1 receptor agonist semaglutide, according to results from the phase III SURPASS-2** trial presented at ADA 2021.
Volagidemab improves glycaemic control in T1D patients

2021-11-12

Phase II data presented at ADA 2021 showed the potential of the GRA* volagidemab to improve glycaemic control in patients with type 1 diabetes (T1D).

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 소현정 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (09:00~18:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2022 KIMS Co., Ltd All Rights Reserved

KIMS APP

KIMS 페이스북

KIMS 트위터